瑞丽医美国际控股有限公司（02135，瑞丽医美）宣布，于即将举行的2026年股东周年大会上，董事会已提请股东批准一项股份购回计划，拟按不超过2026年股东周年大会通过决议当日已发行股份总数10%的上限进行回购。根据公告，瑞丽医美目前已发行股份总数约为5.57亿股，回购上限约为5570.77万股。
根据规划，回购资金来源于公司可合法动用的内部资源或营运资金。董事会指出，此次购回授权符合开曼群岛公司法及香港联合交易所有限公司证券上市规则相关规定，旨在增强每股股份的资产净值及改善资本结构。根据公告，董事会认为适度行使购回授权将有助于提升长期股东回报，符合公司及股东的整体利益。
董事会建议上述购回授权有效期至下次股东周年大会结束前或根据章程细则及适用法律终止之日为止。会议将于2026年6月26日下午三时正举行，股权登记将于6月23日至6月26日（包括首尾两日）暂停办理。有意出席大会并行使表决权的股东需在6月22日下午四时三十分前完成股份过户登记。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.